Brief: Calliditas Therapeutics Announces Full FDA Approval Of TARPEYO
20/12/2023 21:17
Dec 20 (Reuters) - Calliditas Therapeutics AB
CALTX.ST :
* CALLIDITAS THERAPEUTICS ANNOUNCES FULL FDA APPROVAL OF
TARPEYO,
THE ONLY FDA-APPROVED TREATMENT FOR IGA NEPHROPATHY TO
SIGNIFICANTLY REDUCE THE LOSS OF KIDNEY FUNCTION
* TARPEYO WAS GENERALLY WELL-TOLERATED IN PHASE 3 NEFIGARD
CLINICAL TRIAL.
Source text for Eikon: ID:nWkr2NG4y8
Further company coverage: CALTX.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations